| Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy RSI Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Parving HH, Remuzzi G ... New England Journal of Medicine 345 (12), 861-869, 2001 | 9539 | 2001 |
| Dapagliflozin in patients with chronic kidney disease HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ... New England Journal of Medicine 383 (15), 1436-1446, 2020 | 3486 | 2020 |
| Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ... The Lancet 382 (9889), 339-352, 2013 | 2342 | 2013 |
| Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis KG Saag, R Emkey, TJ Schnitzer, JP Brown, F Hawkins, S Goemaere, ... New England Journal of Medicine 339 (5), 292-299, 1998 | 1586 | 1998 |
| Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial R Paniagua, D Amato, E Vonesh, R Correa-Rotter, A Ramos, J Moran, ... Journal of the American Society of Nephrology 13 (5), 1307-1320, 2002 | 1298 | 2002 |
| Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis EVOLVE Trial Investigators New England Journal of Medicine 367 (26), 2482-2494, 2012 | 1017 | 2012 |
| Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ... The Lancet 390 (10105), 1888-1917, 2017 | 907 | 2017 |
| Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial JD Adachi, KG Saag, PD Delmas, UA Liberman, RD Emkey, E Seeman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 718 | 2001 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 491 | 2019 |
| A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis JJ Body, GA Gaich, WH Scheele, PM Kulkarni, PD Miller, A Peretz, ... The Journal of Clinical Endocrinology & Metabolism 87 (10), 4528-4535, 2002 | 455 | 2002 |
| CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy R Correa-Rotter, C Wesseling, RJ Johnson American journal of kidney diseases 63 (3), 506-520, 2014 | 424 | 2014 |
| Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy J Glaser, J Lemery, B Rajagopalan, HF Diaz, R García-Trabanino, ... Clinical Journal of the American Society of Nephrology 11 (8), 1472-1483, 2016 | 405 | 2016 |
| Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the … DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, ... The lancet Diabetes & endocrinology 9 (1), 22-31, 2021 | 342 | 2021 |
| The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy D De Zeeuw, B Coll, D Andress, JJ Brennan, H Tang, M Houser, ... Journal of the American Society of Nephrology 25 (5), 1083-1093, 2014 | 305 | 2014 |
| Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block, R Correa-Rotter, ... Circulation 132 (1), 27-39, 2015 | 303 | 2015 |
| Fructokinase activity mediates dehydration-induced renal injury CAR Jimenez, T Ishimoto, MA Lanaspa, CJ Rivard, T Nakagawa, AA Ejaz, ... Kidney international 86 (2), 294-302, 2014 | 278 | 2014 |
| Dissonant health transition in the states of Mexico, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 H Gómez-Dantés, N Fullman, H Lamadrid-Figueroa, L Cahuana-Hurtado, ... The Lancet 388 (10058), 2386-2402, 2016 | 268 | 2016 |
| Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis JP Devogelaer, H Broll, R Correa-Rotter, DC Cumming, ... Bone 18 (2), 141-150, 1996 | 256 | 1996 |
| Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters M Arlot, PJ Meunier, G Boivin, L Haddock, J Tamayo, R Correa‐Rotter, ... Journal of Bone and Mineral Research 20 (7), 1244-1253, 2005 | 233 | 2005 |
| Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial HJL Heerspink, BV Stefansson, GM Chertow, R Correa-Rotter, T Greene, ... Nephrology Dialysis Transplantation 35 (2), 274-282, 2020 | 224 | 2020 |
